Health-care shares were generally higher in pre-market trade Thursday.
In health-care stocks news, Supernus Pharmaceuticals ( SUPN ) says the FDA has granted fast track designation for SPN-810 to treat impulsive aggression in attention deficit hyperactivity disorder. This product candidate is expected to enter Phase III testing, with patient dosing commencing during 2015.
And, Catalyst Pharmaceutical Partners ( CPRX ) says Q2 non-GAAP net loss was $0.05 per share, smaller than the Thomson Reuters mean for a $0.07 loss. It had zero sales, as expected.
Finally, Perrigo Company ( PRGO ) says Q4 sales were $1.14 billion, beating the Thomson Reuters mean for $1.09194 billion.
Adjusted EPS were $1.74, above estimates for $1.55. FY15 adjusted EPS are seen between $7.20 to $7.50.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.